Emerging roles of TEAD transcription factors and its coactivators in cancers

Cancer Biology and Therapy

Volumn 14, Issue 5, 2013, Pages 390-398

  Pobbati, Ajaybabu V ^a   Hong, Wanjin ^a,b,c  

^a INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c XIAMEN UNIVERSITY   (China)

Author keywords

Cancer; TAZ; TEAD; Vgll proteins; YAP

Indexed keywords

CONNECTIVE TISSUE GROWTH FACTOR; CYSTEINE RICH PROTEIN 61; MYC PROTEIN; NUCLEIC ACID BINDING PROTEIN; PROTEIN P160; PROTEIN TAZ; PROTEIN VGLL; PROTEIN YAP; SURVIVIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR TEAD; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; CANCER GROWTH; CARCINOGENESIS; CELL DIFFERENTIATION; COMPLEX FORMATION; GLIOBLASTOMA; HUMAN; LIVER CANCER; NONHUMAN; OVARY CANCER; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MOTIF; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; TRANSCRIPTION REGULATION;

CANCER; TAZ; TEAD; VGLL PROTEINS; YAP;

ANIMALS; CELL GROWTH PROCESSES; DNA-BINDING PROTEINS; HUMANS; NEOPLASMS; NUCLEAR PROTEINS; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TRANSCRIPTIONAL ACTIVATION;

EID: 84877858820     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.23788     Document Type: Review

References (87)

1. Xiao JH, Davidson I, Ferrandon D, Rosales R, Vigneron M, Macchi M, et al. One cell-specific and three ubiquitous nuclear proteins bind in vitro to overlapping motifs in the domain B1 of the SV40 enhancer. EMBO J 1987; 6:3005-13; PMID:2826126.
2. Ishiji T, Lace MJ, Parkkinen S, Anderson RD, Haugen TH, Cripe TP, et al. Transcriptional enhancer factor (TEF)-1 and its cell-specific co-Activator activate human papillomavirus-16 E6 and E7 oncogene transcription in keratinocytes and cervical carcinoma cells. EMBO J 1992; 11:2271-81; PMID:1318197.
3. Kaneko KJ, Cullinan EB, Latham KE, DePamphilis ML. Transcription factor mTEAD-2 is selectively expressed at the beginning of zygotic gene expression in the mouse. Development 1997; 124:1963-73; PMID:9169843.
4. Chen Z, Friedrich GA, Soriano P. Transcriptional enhancer factor 1 disruption by a retroviral gene trap leads to heart defects and embryonic lethality in mice. Genes Dev 1994; 8:2293-301; PMID:7958896; http://dx.doi.org/10.1101/gad.8.19.2293.
5. Yoshida T. MCAT elements and the TEF-1 family of transcription factors in muscle development and disease. Arterioscler Thromb Vasc Biol 2008; 28:8-17; PMID:17962623; http://dx.doi.org/10.1161/ATVBAHA.107.155788.
6. Milewski RC, Chi NC, Li J, Brown C, Lu MM, Epstein JA. Identification of minimal enhancer elements sufficient for Pax3 expression in neural crest and implication of Tead2 as a regulator of Pax3. Development 2004; 131:829-37; PMID:14736747; http://dx.doi.org/10.1242/dev.00975.
7. Sawada A, Nishizaki Y, Sato H, Yada Y, Nakayama R, Yamamoto S, et al. Tead proteins activate the Foxa2 enhancer in the node in cooperation with a second factor. Development 2005; 132:4719-29; PMID:16207754; http://dx.doi.org/10.1242/dev.02059.
8. Yagi R, Kohn MJ, Karavanova I, Kaneko KJ, Vullhorst D, DePamphilis ML, et al. Transcription factor TEAD4 specifies the trophectoderm lineage at the beginning of mammalian development. Development 2007; 134:3827-36; PMID:17913785; http://dx.doi.org/10.1242/dev.010223.
9. Kaneko KJ, Kohn MJ, Liu C, DePamphilis ML. Transcription factor TEAD2 is involved in neural tube closure. Genesis 2007; 45:577-87; PMID:17868131; http://dx.doi.org/10.1002/dvg.20330.
10. Sawada A, Kiyonari H, Ukita K, Nishioka N, Imuta Y, Sasaki H. Redundant roles of Tead1 and Tead2 in notochord development and the regulation of cell proliferation and survival. Mol Cell Biol 2008; 28:3177-89; PMID:18332127; http://dx.doi.org/10.1128/MCB.01759-07.
11. Anbanandam A, Albarado DC, Nguyen CT, Halder G, Gao X, Veeraraghavan S. Insights into transcription enhancer factor 1 (TEF-1) activity from the solution structure of the TEA domain. Proc Natl Acad Sci U S A 2006; 103:17225-30; PMID:17085591; http://dx.doi.org/10.1073/pnas.0607171103.
12. Xiao JH, Davidson I, Ferrandon D, Rosales R, Vigneron M, Macchi M, et al. One cell-specific and three ubiquitous nuclear proteins bind in vitro to overlapping motifs in the domain B1 of the SV40 enhancer. EMBO J 1987; 6:3005-13; PMID:2826126.
13. Zhao B, Ye X, Yu J, Li L, Li W, Li S, et al. TEAD mediates YAP-dependent gene induction and growth control. Genes Dev 2008; 22:1962-71; PMID:18579750; http://dx.doi.org/10.1101/gad.1664408.
14. Tian W, Yu J, Tomchick DR, Pan D, Luo X. Structural and functional analysis of the YAP-binding domain of human TEAD2. Proc Natl Acad Sci U S A 2010; 107:7293-8; PMID:20368466; http://dx.doi.org/10.1073/pnas.1000293107.
15. Xiao JH, Davidson I, Matthes H, Garnier JM, Chambon P. Cloning, expression, and transcriptional properties of the human enhancer factor TEF-1. Cell 1991; 65:551-68; PMID:1851669; http://dx.doi.org/10.1016/0092-8674(91) 90088-G.
16. Yagi R, Chen LF, Shigesada K, Murakami Y, Ito Y. A WW domain-containing yes-Associated protein (YAP) is a novel transcriptional co-Activator. EMBO J 1999; 18:2551-62; PMID:10228168; http://dx.doi.org/10.1093/emboj/18.9.2551.
17. Voegel JJ, Heine MJ, Tini M, Vivat V, Chambon P, Gronemeyer H. The coactivator TIF2 contains three nuclear receptor-binding motifs and mediates transactivation through CBP binding-dependent and -independent pathways. EMBO J 1998; 17:507-19; PMID:9430642; http://dx.doi.org/10.1093/emboj/17.2.507.
18. Hucl T, Brody JR, Gallmeier E, Iacobuzio-Donahue CA, Farrance IK, Kern SE. High cancer-specific expression of mesothelin (MSLN) is attributable to an upstream enhancer containing a transcription enhancer factor dependent MCAT motif. Cancer Res 2007; 67:9055-65; PMID:17909009; http://dx.doi.org/10.1158/ 0008-5472.CAN-07-0474.
19. Knight JF, Shepherd CJ, Rizzo S, Brewer D, Jhavar S, Dodson AR, et al. TEAD1 and c-Cbl are novel prostate basal cell markers that correlate with poor clinical outcome in prostate cancer. Br J Cancer 2008; 99:1849-58; PMID:19002168; http://dx.doi.org/10.1038/sj.bjc.6604774.
20. Landin Malt A, Cagliero J, Legent K, Silber J, Zider A, Flagiello D. Alteration of TEAD1 expression levels confers apoptotic resistance through the transcriptional up-regulation of Livin. PLoS One 2012; 7:e45498; PMID:23029054; http://dx.doi.org/10.1371/journal. pone.0045498.
21. Han W, Jung EM, Cho J, Lee JW, Hwang KT, Yang SJ, et al. DNA copy number alterations and expression of relevant genes in triple-negative breast cancer. Genes Chromosomes Cancer 2008; 47:490-9; PMID:18314908; http://dx.doi.org/10. 1002/gcc.20550.
22. Richardson AL, Wang ZC, De Nicolo A, Lu X, Brown M, Miron A, et al. X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell 2006; 9:121-32; PMID:16473279; http://dx.doi.org/10.1016/j.ccr.2006.01.013.
23. Nowee ME, Snijders AM, Rockx DA, de Wit RM, Kosma VM, Hämäläinen K, et al. DNA profiling of primary serous ovarian and fallopian tube carcinomas with array comparative genomic hybridization and multiplex ligation-dependent probe amplification. J Pathol 2007; 213:46-55; PMID:17668415; http://dx.doi.org/10.1002/path.2217.
24. Skotheim RI, Autio R, Lind GE, Kraggerud SM, Andrews PW, Monni O, et al. Novel genomic aberrations in testicular germ cell tumors by array-CGH, and associated gene expression changes. Cell Oncol 2006; 28:315-26; PMID:17167184.
25. Hilman D, Gat U. The evolutionary history of YAP and the hippo/YAP pathway. Mol Biol Evol 2011; 28:2403-17; PMID:21415026; http://dx.doi.org/10. 1093/molbev/msr065.
26. Gaffney CJ, Oka T, Mazack V, Hilman D, Gat U, Muramatsu T, et al. Identification, basic characterization and evolutionary analysis of differentially spliced mRNA isoforms of human YAP1 gene. Gene 2012; 509:215-22; PMID:22939869; http://dx.doi.org/10.1016/j.gene.2012.08.025.
27. Ellenberger TE, Brandl CJ, Struhl K, Harrison SC. The GCN4 basic region leucine zipper binds DNA as a dimer of uninterrupted alpha helices: crystal structure of the protein-DNA complex. Cell 1992; 71:1223-37; PMID:1473154; http://dx.doi.org/10.1016/S0092-8674(05)80070-4.
28. Webb C, Upadhyay A, Giuntini F, Eggleston I, Furutani-Seiki M, Ishima R, et al. Structural features and ligand binding properties of tandem WW domains from YAP and TAZ, nuclear effectors of the Hippo pathway. Biochemistry 2011; 50:3300-9; PMID:21417403; http://dx.doi.org/10.1021/bi2001888.
29. Morin-Kensicki EM, Boone BN, Howell M, Stonebraker JR, Teed J, Alb JG, et al. Defects in yolk sac vasculogenesis, chorioallantoic fusion, and embryonic axis elongation in mice with targeted disruption of Yap65. Mol Cell Biol 2006; 26:77-87; PMID:16354681; http://dx.doi.org/10.1128/MCB.26.1.77-87.2006.
30. Makita R, Uchijima Y, Nishiyama K, Amano T, Chen Q, Takeuchi T, et al. Multiple renal cysts, urinary concentration defects, and pulmonary emphysematous changes in mice lacking TAZ. Am J Physiol Renal Physiol 2008; 294:F542-53; PMID:18172001; http://dx.doi.org/10.1152/ajprenal.00201.2007.
31. Hossain Z, Ali SM, Ko HL, Xu J, Ng CP, Guo K, et al. Glomerulocystic kidney disease in mice with a targeted inactivation of Wwtr1. Proc Natl Acad Sci U S A 2007; 104:1631-6; PMID:17251353; http://dx.doi.org/10.1073/pnas. 0605266104.
32. Tian Y, Kolb R, Hong JH, Carroll J, Li D, You J, et al. TAZ promotes PC2 degradation through a SCFbeta-Trcp E3 ligase complex. Mol Cell Biol 2007; 27:6383-95; PMID:17636028; http://dx.doi.org/10.1128/MCB.00254-07.
33. Xu MZ, Chan SW, Liu AM, Wong KF, Fan ST, Chen J, et al. AXL receptor kinase is a mediator of YAPdependent oncogenic functions in hepatocellular carcinoma. Oncogene 2011; 30:1229-40; PMID:21076472; http://dx.doi.org/10.1038/ onc.2010.504.
34. Dong J, Feldmann G, Huang J, Wu S, Zhang N, Comerford SA, et al. Elucidation of a universal sizecontrol mechanism in Drosophila and mammals. Cell 2007; 130:1120-33; PMID:17889654; http://dx.doi.org/10.1016/j.cell.2007.07.019.
35. Camargo FD, Gokhale S, Johnnidis JB, Fu D, Bell GW, Jaenisch R, et al. YAP1 increases organ size and expands undifferentiated progenitor cells. Curr Biol 2007; 17:2054-60; PMID:17980593; http://dx.doi.org/10.1016/j.cub.2007.10. 039.
36. Lian I, Kim J, Okazawa H, Zhao J, Zhao B, Yu J, et al. The role of YAP transcription coactivator in regulating stem cell self-renewal and differentiation. Genes Dev 2010; 24:1106-18; PMID:20516196; http://dx.doi.org/ 10.1101/gad.1903310.
37. Hong W, Guan KL. The YAP and TAZ transcription co-Activators: key downstream effectors of the mammalian Hippo pathway. Semin Cell Dev Biol 2012; 23:785-93; PMID:22659496; http://dx.doi.org/10.1016/j.semcdb.2012.05.004.
38. Varelas X, Wrana JL. Coordinating developmental signaling: novel roles for the Hippo pathway. Trends Cell Biol 2012; 22:88-96; PMID:22153608; http://dx.doi.org/10.1016/j.tcb.2011.10.002.
39. Xu MZ, Yao TJ, Lee NP, Ng IO, Chan YT, Zender L, et al. Yes-Associated protein is an independent prognostic marker in hepatocellular carcinoma. Cancer 2009; 115:4576-85; PMID:19551889; http://dx.doi.org/10.1002/cncr.24495.
40. Zender L, Spector MS, Xue W, Flemming P, Cordon-Cardo C, Silke J, et al. Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell 2006; 125:1253-67; PMID:16814713; http://dx.doi.org/10.1016/j.cell.2006.05.030.
41. Zhang X, George J, Deb S, Degoutin JL, Takano EA, Fox SB, et al.; AOCS Study group. The Hippo pathway transcriptional co-Activator, YAP, is an ovarian cancer oncogene. Oncogene 2011; 30:2810-22; PMID:21317925; http://dx.doi.org/10. 1038/onc.2011.8.
42. Wang Y, Dong Q, Zhang Q, Li Z, Wang E, Qiu X. Overexpression of yes-Associated protein contributes to progression and poor prognosis of non-smallcell lung cancer. Cancer Sci 2010; 101:1279-85; PMID:20219076; http://dx.doi.org/10.1111/j.1349-7006.2010.01511.x.
43. Muramatsu T, Imoto I, Matsui T, Kozaki K, Haruki S, Sudol M, et al. YAP is a candidate oncogene for esophageal squamous cell carcinoma. Carcinogenesis 2011; 32:389-98; PMID:21112960; http://dx.doi.org/10.1093/carcin/bgq254.
44. Fernandez-L A, Northcott PA, Dalton J, Fraga C, Ellison D, Angers S, et al. YAP1 is amplified and up-regulated in hedgehog-Associated medulloblastomas and mediates Sonic hedgehog-driven neural precursor proliferation. Genes Dev 2009; 23:2729-41; PMID:19952108; http://dx.doi.org/10.1101/gad.1824509.
45. Modena P, Lualdi E, Facchinetti F, Veltman J, Reid JF, Minardi S, et al. Identification of tumor-specific molecular signatures in intracranial ependymoma and association with clinical characteristics. J Clin Oncol 2006; 24:5223-33; PMID:17114655; http://dx.doi.org/10.1200/JCO.2006.06.3701.
46. Snijders AM, Schmidt BL, Fridlyand J, Dekker N, Pinkel D, Jordan RC, et al. Rare amplicons implicate frequent deregulation of cell fate specification pathways in oral squamous cell carcinoma. Oncogene 2005; 24:4232-42; PMID:15824737; http://dx.doi.org/10.1038/sj.onc.1208601.
47. Neto-Silva RM, de Beco S, Johnston LA. Evidence for a growth-stabilizing regulatory feedback mechanism between Myc and Yorkie, the Drosophila homolog of Yap. Dev Cell 2010; 19:507-20; PMID:20951343; http://dx.doi.org/10.1016/j. devcel.2010.09.009.
48. Avruch J, Zhou D, Bardeesy N. YAP oncogene overexpression supercharges colon cancer proliferation. Cell Cycle 2012; 11:1090-6; PMID:22356765; http://dx.doi.org/10.4161/cc.11.6.19453.
49. Barry ER, Morikawa T, Butler BL, Shrestha K, de la Rosa R, Yan KS, et al. Restriction of intestinal stem cell expansion and the regenerative response by YAP. Nature 2012;493:106-10; PMID:23178811; http://dx.doi.org/10.1038/ nature11693.
50. Bhat KP, Salazar KL, Balasubramaniyan V, Wani K, Heathcock L, Hollingsworth F, et al. The transcriptional coactivator TAZ regulates mesenchymal differentiation in malignant glioma. Genes Dev 2011; 25:2594-609; PMID:22190458; http://dx.doi.org/10.1101/gad.176800.111.
51. Chan SW, Lim CJ, Guo K, Ng CP, Lee I, Hunziker W, et al. A role for TAZ in migration, invasion, and tumorigenesis of breast cancer cells. Cancer Res 2008; 68:2592-8; PMID:18413727; http://dx.doi.org/10.1158/0008-5472.CAN-07-2696.
52. Lai D, Ho KC, Hao Y, Yang X. Taxol resistance in breast cancer cells is mediated by the hippo pathway component TAZ and its downstream transcriptional targets Cyr61 and CTGF. Cancer Res 2011; 71:2728-38; PMID:21349946; http://dx.doi.org/10.1158/0008-5472.CAN-10-2711.
53. Zhou Z, Hao Y, Liu N, Raptis L, Tsao MS, Yang X. TAZ is a novel oncogene in non-small cell lung cancer. Oncogene 2011; 30:2181-6; PMID:21258416; http://dx.doi.org/10.1038/onc.2010.606.
54. Tanas MR, Sboner A, Oliveira AM, Erickson-Johnson MR, Hespelt J, Hanwright PJ, et al. Identification of a disease-defining gene fusion in epithelioid hemangioendothelioma. Sci Transl Med 2011; 3:98ra82; PMID:21885404; http://dx.doi.org/10.1126/scitranslmed. 3002409.
55. Errani C, Zhang L, Sung YS, Hajdu M, Singer S, Maki RG, et al. A novel WWTR1-CAMTA1 gene fusion is a consistent abnormality in epithelioid hemangioendothelioma of different anatomic sites. Genes Chromosomes Cancer 2011; 50:644-53; PMID:21584898; http://dx.doi.org/10.1002/gcc.20886.
56. Ding L, Ellis MJ, Li S, Larson DE, Chen K, Wallis JW, et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 2010; 464:999-1005; PMID:20393555; http://dx.doi.org/10.1038/nature08989.
57. Liu-Chittenden Y, Huang B, Shim JS, Chen Q, Lee SJ, Anders RA, et al. Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. Genes Dev 2012; 26:1300-5; PMID:22677547; http://dx.doi.org/10.1101/gad.192856.112.
58. Yu FX, Zhao B, Panupinthu N, Jewell JL, Lian I, Wang LH, et al. Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling. Cell 2012; 150:780-91; PMID:22863277; http://dx.doi.org/10.1016/j.cell.2012.06. 037.
59. Mo JS, Yu FX, Gong R, Brown JH, Guan KL. Regulation of the Hippo-YAP pathway by proteaseactivated receptors (PARs). Genes Dev 2012; 26:2138-43; PMID:22972936; http://dx.doi.org/10.1101/gad.197582.112.
60. Dorsam RT, Gutkind JS. G-protein-coupled receptors and cancer. Nat Rev Cancer 2007; 7:79-94; PMID:17251915; http://dx.doi.org/10.1038/nrc2069.
61. Strano S, Munarriz E, Rossi M, Castagnoli L, Shaul Y, Sacchi A, et al. Physical interaction with Yes-Associated protein enhances p73 transcriptional activity. J Biol Chem 2001; 276:15164-73; PMID:11278685; http://dx.doi.org/10. 1074/jbc.M010484200.
62. Basu S, Totty NF, Irwin MS, Sudol M, Downward J. Akt phosphorylates the Yes-Associated protein, YAP, to induce interaction with 14-3-3 and attenuation of p73-mediated apoptosis. Mol Cell 2003; 11:11-23; PMID:12535517; http://dx.doi.org/10.1016/S1097-2765(02)00776-1.
63. Vaudin P, Delanoue R, Davidson I, Silber J, Zider A. TONDU (TDU), a novel human protein related to the product of vestigial (vg) gene of Drosophila melanogaster interacts with vertebrate TEF factors and substitutes for Vg function in wing formation. Development 1999; 126:4807-16; PMID:10518497.
64. Faucheux C, Naye F, Treguer K, Fedou S, Thiebaud P, Theze N. Vestigial like gene family expression in Xenopus: common and divergent features with other vertebrates. Int J Dev Biol 2012;54:1375-82; PMID:20712000; http://dx.doi.org/10.1387/ijdb.103080cf.
65. Pobbati AV, Chan SW, Lee I, Song H, Hong W. Structural and functional similarity between the Vgll1-TEAD and the YAP-TEAD complexes. Structure 2012; 20:1135-40; PMID:22632831; http://dx.doi.org/10.1016/j.str.2012.04.004.
66. Blaveri E, Simko JP, Korkola JE, Brewer JL, Baehner F, Mehta K, et al. Bladder cancer outcome and subtype classification by gene expression. Clin Cancer Res 2005; 11:4044-55; PMID:15930339; http://dx.doi.org/10.1158/1078-0432. CCR-04-2409.
67. Maeda T, Chapman DL, Stewart AF. Mammalian vestigial-like 2, a cofactor of TEF-1 and MEF2 transcription factors that promotes skeletal muscle differentiation. J Biol Chem 2002; 277:48889-98; PMID:12376544; http://dx.doi.org/10.1074/jbc.M206858200.
68. Maeda T, Gupta MP, Stewart AF. TEF-1 and MEF2 transcription factors interact to regulate musclespecific promoters. Biochem Biophys Res Commun 2002; 294:791-7; PMID:12061776; http://dx.doi.org/10.1016/S0006-291X(02)00556-9.
69. Günther S, Mielcarek M, Krüger M, Braun T. VITO-1 is an essential cofactor of TEF1-dependent muscle-specific gene regulation. Nucleic Acids Res 2004; 32:791-802; PMID:14762206; http://dx.doi.org/10.1093/nar/gkh248.
70. Johnson CW, Hernandez-Lagunas L, Feng W, Melvin VS, Williams T, Artinger KB. Vgll2a is required for neural crest cell survival during zebrafish craniofacial development. Dev Biol 2011; 357:269-81; PMID:21741961; http://dx.doi.org/10.1016/j.ydbio.2011.06.034.
71. Mielcarek M, Piotrowska I, Schneider A, Günther S, Braun T. VITO-2, a new SID domain protein, is expressed in the myogenic lineage during early mouse embryonic development. Gene Expr Patterns 2009; 9:129-37; PMID:19118645; http://dx.doi.org/10.1016/j.gep.2008.12.002.
72. Halperin DS, Pan C, Lusis AJ, Tontonoz P. Vestigial-like 3 (Vgll3) is an Inhibitor of Adipocyte Differentiation. J Lipid Res 2012;54:473-81; PMID:23152581; http://dx.doi.org/10.1194/jlr.M032755.
73. Hélias-Rodzewicz Z, Pérot G, Chibon F, Ferreira C, Lagarde P, Terrier P, et al. YAP1 and VGLL3, encoding two cofactors of TEAD transcription factors, are amplified and overexpressed in a subset of soft tissue sarcomas. Genes Chromosomes Cancer 2010; 49:1161-71; PMID:20842732; http://dx.doi.org/10.1002/gcc.20825.
74. Hallor KH, Sciot R, Staaf J, Heidenblad M, Rydholm A, Bauer HC, et al. Two genetic pathways, t(1;10) and amplification of 3p11-12, in myxoinflammatory fibroblastic sarcoma, haemosiderotic fibrolipomatous tumour, and morphologically similar lesions. J Pathol 2009; 217:716-27; PMID:19199331; http://dx.doi.org/ 10.1002/path.2513.
75. Cody NA, Shen Z, Ripeau JS, Provencher DM, Mes-Masson AM, Chevrette M, et al. Characterization of the 3p12.3-pcen region associated with tumor suppression in a novel ovarian cancer cell line model genetically modified by chromosome 3 fragment transfer. Mol Carcinog 2009; 48:1077-92; PMID:19347865; http://dx.doi.org/10.1002/mc.20535.
76. Chen HH, Mullett SJ, Stewart AF. Vgl-4, a novel member of the vestigial-like family of transcription cofactors, regulates alpha1-Adrenergic activation of gene expression in cardiac myocytes. J Biol Chem 2004; 279:30800-6; PMID:15140898; http://dx.doi.org/10.1074/jbc.M400154200.
77. Teng AC, Kuraitis D, Deeke SA, Ahmadi A, Dugan SG, Cheng BL, et al. IRF2BP2 is a skeletal and cardiac muscle-enriched ischemia-inducible activator of VEGFA expression. FASEB J 2010; 24:4825-34; PMID:20702774; http://dx.doi.org/10.1096/fj.10-167049.
78. Jin HS, Park HS, Shin JH, Kim DH, Jun SH, Lee CJ, et al. A novel inhibitor of apoptosis protein (IAP)-interacting protein, Vestigial-like (Vgl)-4, counteracts apoptosis-inhibitory function of IAPs by nuclear sequestration. Biochem Biophys Res Commun 2011; 412:454-9; PMID:21839727; http://dx.doi.org/10.1016/j.bbrc.2011.07.117.
79. Mann KM, Ward JM, Yew CC, Kovochich A, Dawson DW, Black MA, et al.; Australian Pancreatic Cancer Genome Initiative. Sleeping Beauty mutagenesis reveals cooperating mutations and pathways in pancreatic adenocarcinoma. Proc Natl Acad Sci U S A 2012; 109:5934-41; PMID:22421440; http://dx.doi.org/10.1073/ pnas.1202490109.
80. Belandia B, Parker MG. Functional interaction between the p160 coactivator proteins and the transcriptional enhancer factor family of transcription factors. J Biol Chem 2000; 275:30801-5; PMID:10934189; http://dx.doi.org/10.1074/jbc.C000484200.
81. Chen L, Chan SW, Zhang X, Walsh M, Lim CJ, Hong W, et al. Structural basis of YAP recognition by TEAD4 in the hippo pathway. Genes Dev 2010; 24:290-300; PMID:20123908; http://dx.doi.org/10.1101/gad.1865310.
82. Li Z, Zhao B, Wang P, Chen F, Dong Z, Yang H, et al. Structural insights into the YAP and TEAD complex. Genes Dev 2010; 24:235-40; PMID:20123905; http://dx.doi.org/10.1101/gad.1865810.
83. Darimont BD, Wagner RL, Apriletti JW, Stallcup MR, Kushner PJ, Baxter JD, et al. Structure and specificity of nuclear receptor-coactivator interactions. Genes Dev 1998; 12:3343-56; PMID:9808622; http://dx.doi.org/10.1101/gad.12.21. 3343.
84. Fossdal R, Jonasson F, Kristjansdottir GT, Kong A, Stefansson H, Gosh S, et al. A novel TEAD1 mutation is the causative allele in Sveinsson's chorioretinal atrophy (helicoid peripapillary chorioretinal degeneration). Hum Mol Genet 2004; 13:975-81; PMID:15016762; http://dx.doi.org/10.1093/hmg/ddh106.
85. Sudol M, Shields DC, Farooq A. Structures of YAP protein domains reveal promising targets for development of new cancer drugs. Semin Cell Dev Biol 2012; 23:827-33; PMID:22609812; http://dx.doi.org/10.1016/j.semcdb.2012.05.002.
86. Moellering RE, Cornejo M, Davis TN, Del Bianco C, Aster JC, Blacklow SC, et al. Direct inhibition of the NOTCH transcription factor complex. Nature 2009; 462:182-8; PMID:19907488; http://dx.doi.org/10.1038/nature08543.
87. Halder G, Carroll SB. Binding of the Vestigial co-factor switches the DNA-target selectivity of the Scalloped selector protein. Development 2001; 128:3295-305; PMID:11546746.